Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy
Donofrio, Peter D.; Tandan, Rup; Albers, James W.
1985-05
Citation
Donofrio, Peter D.; Tandan, Rup; Albers, James W. (1985)."Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy." Muscle & Nerve 8(4): 321-327. <http://hdl.handle.net/2027.42/50135>
Abstract
Eleven consecutive patients with progressive chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) underwent plasma exchange. Eight patients were previously unresponsive to prednisone, two were started on prednisone with plasma exchange, and one did not receive corticosteroids. Electrodiagnostic studies revealed evidence of an acquired demyelinating polyradiculoneuropathy with varying degrees of axonal degeneration. Neurologic impairment was monitored using conventional functional status index. Five patients demonstrated substantial clinical improvement, beginning 2 days to 3 weeks after initiating plasma exchange. Two additional patients improved following a second course of plasma exchange, and four patients demonstrated minimal or no change. Comparison of responding and onresponding patients showed no differences related to the presence or absence of antecedent illness, duration of disease, duration of maximum weakness, or severity of impairment prior to plasma exchange. Responders had significantly prolonged F-response and motor distal latencies compared to nonresponders. Results in this unselected, consecutive patient trial suggest a temporal relationship between plasma exchange and clinical improvement in some patients with progressive CIDP.Publisher
Wiley Subscription Services, Inc., A Wiley Company
ISSN
0148-639X 1097-4598
Other DOIs
PMID
16758599
Types
Article
URI
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16758599&dopt=citationMetadata
Show full item recordAccessibility: If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.